[Chemotherapy of lymphogranulomatosis].
D000293:Adolescent; D000367:Age Factors; D000970:Antineoplastic Agents / Q000009:adverse effects; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D007111:Immunity, Cellular; D007958:Leukocyte Count; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D012075:Remission, Spontaneous; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004338:Drug Combinations; D002699:Chlorambucil; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D011241:Prednisone
Chemotherapie der Lymphogranulomatose